CRISPR/Cas9 screening revealed BIRC6-AS1/BIRC6 mediates abiraterone resistance via NHEJ pathway-dependent A20 degradation in prostate cancer.
- DOI
- 10.1038/s41388-026-03977-5
- Published
- 2026 Sep 17
- Container
- Oncogene
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41388-026-03977-5,
title = {CRISPR/Cas9 screening revealed BIRC6-AS1/BIRC6 mediates abiraterone resistance via NHEJ pathway-dependent A20 degradation in prostate cancer.},
author = {Li L and An XN and Ruan YT and Yang R and Li P and Shen PT and Zeng HY and Wu XY and Huang XC and Song MY and Hao JL and Gao P and Dong XM},
year = {2026},
journal = {Oncogene},
doi = {10.1038/s41388-026-03977-5},
url = {https://doi.org/10.1038/s41388-026-03977-5}
}RIS
TY - JOUR TI - CRISPR/Cas9 screening revealed BIRC6-AS1/BIRC6 mediates abiraterone resistance via NHEJ pathway-dependent A20 degradation in prostate cancer. AU - Li L AU - An XN AU - Ruan YT AU - Yang R AU - Li P AU - Shen PT AU - Zeng HY AU - Wu XY AU - Huang XC AU - Song MY AU - Hao JL AU - Gao P AU - Dong XM PY - 2026 JO - Oncogene DO - 10.1038/s41388-026-03977-5 UR - https://doi.org/10.1038/s41388-026-03977-5 ER -
APA
L, L., XN, A., YT, R., R, Y., P, L., PT, S., HY, Z., XY, W., XC, H., MY, S., JL, H., P, G., & XM, D. (2026). CRISPR/Cas9 screening revealed BIRC6-AS1/BIRC6 mediates abiraterone resistance via NHEJ pathway-dependent A20 degradation in prostate cancer.. Oncogene. https://doi.org/10.1038/s41388-026-03977-5
Source records
- pubmed · retrieved 2026-09-25T17:56:06.818Z